ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study

 ADC Therapeutics and Sophia Genetics Collaborate to Identify Biomarkers in Clinical Study

Shots:

  • The companies enter into a collaboration to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine). ADC Therapeutics is currently assessing ADCT-402 in P-II study in patients with r/r DLBCL
  • Sophia Genetic will analyze cell-free DNA (cfDNA) samples extracted from blood patients participating in ADC Therapeutics’ Phase II study utilizing Sophia’s technology, detecting genomic marker with clinical response to ADCT-402 
  • ADCT-402 is an ADC consisting of humanized mAb, binding to CD19 via linker to PBD dimer toxin and is being evaluated in P-Ib (NCT03684694) & P-Ib (NCT03685344) studies in combination with ibrutinib & durvalumab for R/R DLBCL or MCL & R/R DLBCL, MCL, FL respectively

Click here to­ read full press release/ article | Ref: ADC Therapeutics| Image: ADC therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post